Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer

Atsushi Sekiguchi1,2,*, Chiho Sato3,4,*, Izumi Matsudaira5, Yuka Kotozaki6, Rui Nouchi7,8,9, Hikaru Takeuchi10, Masaaki Kawai10, Hiroshi Tada4, Takanori Ishida4, Yasuyuki Takii, Noriaki Ohuchi4 & Ryuta Kawashima3,9,10

Cancer survivors are exposed to several risk factors for cognitive dysfunction, such as general anesthesia, surgical trauma, and adjuvant therapies. In our recent study we showed that thalamic volume reduction and attentional dysfunction occurred shortly after surgery. Here, we examined the 6-month prognosis of the 20 patients with breast cancer who underwent surgery. Seven patients did not receive any adjuvant therapy after the surgery and 13 patients received a hormonal therapy after the surgery. We assessed their attentional functions, and thalamic volumes shortly after and 6 months after surgery. We found a significant group x time interaction in the attentional functions (p = 0.033) and the right thalamus (p < 0.05, small volume correction), suggesting the thalamic volume reduction and attentional dysfunction recovered in patients without adjuvant therapy. Our findings provide a better understanding of the potential role of hormonal therapy in relation to the cognitive dysfunction of cancer survivors.

Cancer survivors are exposed to several risk factors for cognitive dysfunction, such as general anesthesia, surgical trauma, the occurrence of complications, and adjuvant therapies1–5. The cognitive dysfunction after surgery is known as postoperative cognitive dysfunction (POCD)1–3. General anesthesia and inflammation due to surgical trauma or complications are considered the principal causes of POCD6–8. Similarly, the cognitive dysfunction caused by chemotherapy is a side effect of cancer therapy. Many anticancer drugs have neurotoxic effects, which cause cognitive dysfunction and brain atrophy9 termed “Chemo-brain”4,10.

The maintenance of cognitive function is important to preserve the quality of life (QOL) for breast cancer survivors11,12, because of the long-term survivorship. Previous studies have reported that cognitive dysfunction in patients with breast cancer may originate in neuron injuries caused by chemotherapy13, represented by abnormalities of specific brain structures14,15 and brain functions16,17. Similarly, cognitive functions were reported impaired by hormonal therapy5,18 and improved after the cessation of treatment19. However, a neuropathology of the cognitive dysfunction due to hormonal therapy remains unclear.

1Department of Adult Mental Health, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan.
2Division of Medical Neuroimage Analysis, Department of Community Medical Supports, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
3Department of Functional Brain Imaging, Institute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan.
4Division of Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan.
5Department of Nuclear Medicine and Radiology, IDAC, Tohoku University, Sendai, Japan.
6Division of Clinical Research, Medical-Industry Translational Research Center, Fukushima Medical University School of Medicine, Fukushima, Japan.
7Creative Interdisciplinary Research Division, Frontier Research Institute for Interdisciplinary Science, Tohoku University, Sendai, Japan.
8Human and Social Response Research Division, International Research Institute of Disaster Science, Tohoku University, Sendai, Japan.
9Department of Advanced Brain Science, Smart Ageing International Research Center, IDAC, Tohoku University, Sendai, Japan.
10Division of Developmental Cognitive Neuroscience, IDAC, Tohoku University, Sendai, Japan.
11Department of Breast Oncology, Miyagi Cancer Center Hospital, Miyagi, Japan.
*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to A.S. (email: asekiguchi@ncnp.go.jp)
In our recent study, we investigated the cognitive dysfunction and brain structural changes shortly after surgery in patients with breast cancer and found thalamic volume reduction and attentional dysfunction were early responses to general anesthesia. The results suggest the early postoperative response to anesthesia may represent an intermediate phenotype of POCD. Based on the previous findings of high incidence of POCD shortly after surgery, and rapid attenuation of symptoms as time progressed, we assumed patients who underwent surgery with general anesthesia were similarly affected by the anesthesia and that a majority of these patients would fully recover after surgery if not exposed to other risk factors. Therefore, further investigations to distinguish the effects of hormonal therapy on brain structural changes and cognitive dysfunction are necessary.

To address this issue, we investigated these patients 6 months after surgery to clarify the prognosis of thalamic volume reduction and attentional dysfunction. To examine the effect of hormonal therapy, we controlled the risk factors for cognitive dysfunction after the surgery other than hormonal therapy. We hypothesized that thalamic volume reduction and attentional dysfunction would recover in patients without hormonal therapy and not in those with hormonal therapy.

### Materials and Methods

#### Participants.
Thirty-two patients from our previous study who underwent breast cancer surgery were screened for eligibility in the current follow-up study. To control the effects of chemotherapy on cognitive function and brain, four patients who received chemotherapy after the surgery were excluded. Furthermore, to control the effects of serum estrogen levels on the brain, three patients who received hormonal therapy with a selective estrogen receptor modulator (SERM) such as tamoxifen were excluded, because SERMs do not decrease serum estrogen levels, whereas an aromatase inhibitor (AI) does. Five patients declined to participate in this study because they were either uninterested, or too busy. Finally, 20 postmenopausal women with early-stage breast cancer were enrolled in the current follow-up study. Patients did not receive any adjuvant therapy after the surgery (Ho group), while 13 patients received hormonal therapy with an AI after the surgery (Wo group). Demographic characteristics of patients are shown in Table 1. Written informed consent was obtained from each subject. The Ethics Committee of the Tohoku University Graduate School of Medicine approved this study. The methods of this study were also carried out in accordance with the approved guidelines.

#### Protocol.
Postoperative assessments were performed during hospitalization and follow-up assessments were performed when the participants came to the hospital as outpatients. Postoperative assessments were performed within 1 week of surgery (Post), and follow-up assessments were performed approximately 6 months after the surgery (Follow-up). Because the present study was observational in design, there were no restrictions on the types of anesthesia used. Assessments were also performed shortly before the surgery (for details, see). The study was registered in the University Hospital Medical Information Network (UMIN) Clinical Trial Registry (UMIN 000007287).

#### Psychological measurements.
To evaluate the effect of adjuvant hormonal therapy, we assessed attentional function using the Digit Cancellation Test (D-CAT), which has been well validated in a Japanese population. Given that we identified attentional dysfunction shortly after surgery using the D-CAT1 score in our previous investigation, we focused on this score in the present follow-up study. The test sheet consisted of 12 rows of 50 digits, each containing five sets of numbers from 0–9 arranged randomly. Participants were instructed to identify the target number (6) with a slash mark as quickly and accurately as possible within 1 min. Based on the data from a Japanese population of each sex and age range, we regarded scores < mean − 1 standard deviation in each age range (50 s: < 23, 60 s: < 19, 70 s: < 16) as impaired.

#### Image acquisition.
All MRI data were acquired using a 3-T Philips Intera Achieva scanner (Best, Netherlands). A magnetization-prepared rapid gradient echo (MPRAGE) sequence was used to collect...
SVC was applied to one region of interest (ROI) based on our previous findings (right thalamus) using age, total brain volumes and the right thalamic volumes at post as covariates. Small volume corrected differences in the absolute amount of brain tissue to be determined were also performed using SPSS 18 (SPSS, Chicago, IL, USA).

Follow-up interaction using an analysis of covariance (ANCOVA) model on SPM8. The analyses were performed using SPSS 18 (SPSS, Chicago, IL, USA).

All statistical analyses were performed using SPSS 18 (SPSS, Chicago, IL, USA).

We found a significant group × time interaction in the D-CAT1 scores (Wo: 30.0 ± 1.9 to 32.3 ± 2.2, Ho: 30.5 ± 6.1 to 29.0 ± 5.4, p = 0.033, Fig. 1). Although the scores were estimated within normal ranges and attentional dysfunction was relatively mild, the results showed that attentional function improved in the Wo group but not in the Ho group over time.
We found a significant group x time interaction in the rGMV in the right thalamus (x = 6, y = −12, z = −2; p < 0.05, svc, Fig. 2). The estimated values of the right thalamic volumes were significantly increased in the Wo group (Wo: 0.254 ± 0.022 to 0.263 ± 0.023, p < 0.05, paired t-test), but not in the Ho group (0.245 ± 0.019 to 0.237 ± 0.029, p = 0.13, paired t-test).

No association was detected between the change in the ratio of the D-CAT1 score and right thalamic volume (r = 0.26, p = 0.28).

Discussion

This was the first study to examine the impacts of hormonal therapy on brain structural changes and cognitive dysfunction in patients with breast cancer. We found the right thalamic volume reduction and attentional dysfunction recovered shortly after the surgery in the Wo group but not in the Ho group. The findings support our hypothesis that thalamic volume reduction and attentional dysfunction would recover in patients without an adjuvant hormonal therapy.

Our findings suggest that hormonal therapy prevents recovery of brain volume reduction and cognitive dysfunction shortly after surgery in patients with breast cancer. Reportedly, cognitive functions were impaired by hormonal therapy5,18 and improved after the cessation of treatment19. Conversely, brain structural changes due to hormonal therapy remained unclear. Since estrogen protects neuronal cells25,26, hormonal therapy may impair neurons by reducing the neuroprotective effects of estrogen. Based on our findings, even if hormonal therapy does not have direct neurotoxic effects, hormonal therapy prevents recovery of neuronal damage caused by other neurotoxic agents, such as an anesthesia, inflammation and chemotherapy. Therefore, we hypothesized that hormonal therapy is a factor inhibiting recovery from neuronal damage and cognitive dysfunction.

The above mentioned notion is relevant for a pathogenesis of POCD. Manifestation of POCD comprised dysfunction in various cognitive domains1 and affected large areas of brain regions27. The variation of POCD is apparently associated with multiple risk factors27, including age, lower educational level, pre-existing cognitive impairment, long duration of anesthesia, surgery-induced systematic inflammation and complications after surgery2,3. In line with the multiple risk factors for POCD, hormonal therapy for breast cancer patients can also be considered an additional risk factor for POCD. In the case of hormonal therapy, reduced neuroprotective effects would inhibit a recovery from different forms of neuronal damage, due to various causes. Therefore, we assumed that predicting specific cognitive domains and brain regions impaired by hormonal therapy would be difficult.

In the present study, even if we revealed one aspect of hormonal therapy as a risk factor for cognitive dysfunction, we did not intend to recommend reducing the dose and/or duration of hormonal therapy. Instead, we proposed improving adherence to hormonal therapy medications by an appropriate assessment and rehabilitation of cognitive dysfunction. Regarding hormonal therapy for breast cancer, long-term medication was recommended to achieve a better prognosis28,29. A 10-year treatment can approximately halve breast cancer mortality, as opposed to discontinuing treatment after 5 years30. Therefore, to improve the recurrence and mortality rates, adherence to medications is crucial in hormonal therapy for breast cancer28,29. Because adherence to medications was significantly reduced in patients with cognitive dysfunction31, an appropriate cognitive rehabilitation or training32,33 could contribute to a better prognosis, by improving adherence. We thought that the effect of cognitive dysfunction on compliance was too subtle to be noticed. Therefore, a better evaluation, and an attempt to treat the cognitive dysfunction, may lead to better treatment.

Our study had several strengths and a limitation. The strength of the current study was controlling other risk factors for cognitive dysfunction, other than hormonal therapy. Additionally, the prospective cohort design and a uniform protocol of MRI scanning were strengths. Accordingly, we successfully detected the recovery of the right thalamic volume reduction and attentional dysfunction shortly after surgery. A limitation of this study included small sample size, specifically in the Wo group, which limited the topics examined. Further studies investigating larger numbers of breast cancer survivors are necessary.
Despite the limitation, the findings support our hypothesis that the thalamic volume reduction and the attentional dysfunction would recover in patients without an adjuvant therapy. In our previous study, we demonstrated that the general anesthesia impacts brain and its functions in cancer survivors. However, most survivors would recover after surgery if not exposed to other risk factors, the occurrence of complications, and adjuvant therapies including hormonal therapies. Our findings provide a better understanding of the role of hormonal therapy in relation to cognitive dysfunction in breast cancer survivors.

References
1. Moller, I. T. et al. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 351, 857–861 (1998).
2. Monk, T. G. et al. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology 108, 18–30, doi: 10.1097/01.anes.0000296071.19434.1e (2008).
3. Price, C. G., Garvan, C. W. & Monk, T. G. Type and severity of cognitive decline in older adults after noncardiac surgery. Anesthesiology 108, 8–17, doi: 10.1097/01.anes.0000296072.02527.18 (2008).
4. Taillibert, S., Voillery, D. & Bernard-Marty, C. Chemobrain: is systemic chemotherapy neurotoxic? Current opinion in oncology 19, 623–627, doi: 10.1097/CCO.0b013e3282e0224.20071100-00015 [pii] (2007).
5. Collins, B., Mackenzie, J., Stewart, A., Bialojaj, C. & Verma, S. Cognitive effects of hormonal therapy in early stage breast cancer patients: a prospective study. Psycho-oncology 18, 811–821, doi: 10.1002/pon.1453 (2009).
6. Terrando, N. et al. Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline. Proceedings of the National Academy of Sciences of the United States of America 107, 20518–20522, doi: 10.1073/pnas.1014557107 (2010).
7. Cao, X. Z. et al. Postoperative cognitive deficits and neuroinflammation in the hippocampus triggered by surgical trauma are exacerbated in aged rats. Progress in neuro-psychopharmacology & biological psychiatry 34, 1426–1432, doi: 10.1016/j.pnpb.2010.07.027 (2010).
8. Hfocer, R. D. et al. Cell age-specific vulnerability of neurons to anesthetic toxicity. Annals of neurology 73, 695–704, doi: 10.1002/ana.23892 (2013).
9. Ahles, T. A., Root, J. C. & Ryan, E. L. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 30, 5675–5686, doi: 10.1200/JCO.2012.43.0116 (2012).
10. Staat, K. & Segatore, M. The phenomenon of chemo brain. Clinical journal of oncology nursing 9, 713–721, doi: 10.1188/05.CJON.713-721 (2005).
11. Matsuda, T. et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 12, 279–287 (2005).
12. Ahles, T. A. et al. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 4399–4405, doi: 10.1200/JCO.2005.03.343 (2005).
13. Fan, H. G. et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 8025–8032, doi: 23/31/8025 [pii] 10.1200/JCO.2003.01.6550 (2005).
14. McDonald, B. C., Conroy, S. K., Ahles, T. A., West, J. D. & Säkin, A. J. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast cancer research and treatment 123, 819–828, doi: 10.1007/s10549-010-1088-4 (2010).
15. Deprez, S. et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Human brain mapping 32, 480–493, doi: 10.1002/hbm.21033 (2011).
16. Kesler, S. R., Bennett, E. C., Mahaffey, M. L. & Spiegel, D. Regional brain activation during verbal declarative memory in metastatic breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research 15, 6665–6673, doi: 10.1158/0166-6224.CCR-09-1227 (2009).
17. de Ruiter, M. B. et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Human brain mapping 32, 1206–1219, doi: 10.1002/hbm.21102 (2011).
18. Phillips, K. A. et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial. Breast 19, 388–395, doi: 09960-9776[1000079-2 [pii] 10.1016/j.breast.2010.03.025 (2010).
19. Phillips, K. A. et al. Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial. Breast cancer research and treatment 126, 221–226, doi: 10.1007/s10549-010-1235-y (2011).
20. Sato, C. et al. Postoperative Structural Brain Changes and Cognitive Dysfunction in Patients with Breast Cancer. PloS one 10, e0140655, doi: 10.1371/journal.pone.0140655 (2015).
21. Hatta, T., Ito, Y. & Yoshizaki, K. D-CAT manual: Screening test for attention Union Press, Osaka (2006).
22. Ashburner, J. & Friston, K. J. Voxel-based morphometry—the methods. Neuroimage 11, 805–821, doi: 10.1016/ning.2000.00528 (2000).
23. Lancaster, J., et al. Automated Talairach atlas labels for functional brain mapping. Human brain mapping 10, 120–131 (2000).
24. Maldjian, J. A., Lauriést, P. J., Kraft, R. A. & Burdette, J. H. An automated method for neuroanatomical and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage 19, 1233–1239 (2003).
25. Green, P. S. & Simpkins, J. W. Neuroprotective effects of estrogens: potential mechanisms of action. International journal of developmental neuroscience: the official journal of the International Society for Developmental Neuroscience 18, 347–358 (2000).
26. McEwen, B. Estrogen actions throughout the brain. Recent progress in hormone research 57, 337–384 (2002).
27. Hovens, I. B. et al. Thinking through postoperative cognitive dysfunction: How to bridge the gap between clinical and pre-clinical perspectives. Brain, behavior, and immunity 26, 1169–1179, doi: 10.1016/j.bbi.2012.06.004 (2012).
28. Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805–816, doi: 10.1016/S0140-6736(12)61963-1 (2013).
29. Taketani, K. et al. Early discontinuation of adjuvant hormone therapy is associated with a poor prognosis in Japanese breast cancer patients. Surgery today 44, 1841–1846, doi: 10.1002/slt.00762-7 (2014).
30. Moore, S. Nonadherence in patients with breast cancer receiving oral therapies. Clinical journal of oncology nursing 14, 41–47, doi: 10.1188/10.CJON.41-47 (2010).
31. Hershman, D. L. et al. Early discontinuation and non-adherence to hormonal adjuvant therapy are associated with increased mortality in women with breast cancer. Breast cancer research and treatment 126, 529–537, doi: 10.1007/s10549-010-1132-4 (2011).
32. Price, C. G., Vincent, A. S., Guthery, L. & Prodan, C. I. Cognitive impairments is associated with medication nonadherence in asymptomatic carotid stenosis. The American journal of medicine 127, 1243–1246, doi: 10.1016/j.amjmed.2014.08.010 (2014).
33. Ercoli, L. M. et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. Psycho-oncology 24, 1360–1367, doi: 10.1002/pno.3769 (2015).
34. Kesler, S. et al. Cognitive training for improving executive function in chemotherapy-treated breast cancer survivors. Clinical breast cancer 13, 299–306, doi: 10.1016/j.clbc.2013.02.004 (2013).
Acknowledgements
We thank our study participants, the psychological test examiners, and all of our colleagues at the Institute of Development, Aging, and Cancer and at Tohoku University Hospital for their support. Our study was conducted using a Grant-in-Aid for Young Scientists (B) (KAKENHI 24790653) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT).

Author Contributions
A.S., C.S., M.K., Y.K., R.N., H. Takeuchi, H. Tada, T.I., Y.T., N.O. and R.K. conceived and designed the experiments; A.S., C.S., M.K., Y.K., R.N., H. Takeuchi and H. Tada performed the experiments; A.S., C.S. and I.M. analyzed the data; A.S., C.S., R.N. and H. Takeuchi contributed reagents/materials/analysis tools; A.S. and C.S. wrote the manuscript, which was reviewed by all authors.

Additional Information
Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Sekiguchi, A. et al. Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer. Sci. Rep. 6, 34671; doi: 10.1038/srep34671 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016